FCCC LOGO Faculty Publications
Mohler JL , Kantoff PW , Armstrong AJ , Bahnson RR , Cohen M , D'Amico AV , Eastham JA , Enke CA , Farrington TA , Higano CS , Horwitz EM , Kawachi MH , Kuettel M , Lee RJ , MacVicar GR , Malcolm AW , Miller D , Plimack ER , Pow-Sang JM , Richey S , Roach M , Rohren E , Rosenfeld S , Small EJ , Srinivas S , Stein C , Strope SA , Tward J , Walsh PC , Shead DA , Ho M
Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
Journal of the National Comprehensive Cancer Network. 2013 Dec;11(12) :1471-1479
PMID: WOS:000328639000005   
Back to previous list
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
Mohler, James L. Kantoff, Philip W. Armstrong, Andrew J. Bahnson, Robert R. Cohen, Michael D'Amico, Anthony Victor Eastham, James A. Enke, Charles A. Farrington, Thomas A. Higano, Celestia S. Horwitz, Eric Mark Kawachi, Mark H. Kuettel, Michael Lee, Richard J. MacVicar, Gary R. Malcolm, Arnold W. Miller, David Plimack, Elizabeth R. Pow-Sang, Julio M. Richey, Sylvia Roach, Mack, III Rohren, Eric Rosenfeld, Stan Small, Eric J. Srinivas, Sandy Stein, Cy Strope, Seth A. Tward, Jonathan Walsh, Patrick C. Shead, Dorothy A. Ho, Maria